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Abstract
Objective: Endovascular intervention is commonly pursued as first-line management of
symptomatic, long-segment superficial femoral artery (SFA) disease. The relative
effectiveness and comparative long-term outcomes among bare metal stents (BMSs), covered
stents (CSs), and drug-eluting stents (DESs) for long-segment SFA lesions remain uncertain.

Methods: A retrospective cohort study identified patients with symptomatic SFA lesions
measuring at least 15cm who successfully received an endovascular stent (BMS, CS, or
DES). The outcomes were patency, patient presentation upon stent occlusion, amputationfree survival (AFS), and all-cause mortality. Proportional hazards regressions and a
multinomial logistic regression model were used to control for significant confounders.

Results: A total of 226 procedures were analyzed (BMS: 95 [42%]; CS: 74 [33%]; DES: 57
[25%]). There were no significant differences among the three stent types with respect to age,

prevalence of either diabetes or end-stage renal disease, or smoking history. The median
length of the SFA lesion varied across the cohorts (BMS: 28cm (interquartile range [IQR]
20-30cm); CS: 26cm [IQR 20-30cm]; DES: 20cm [IQR 16-25cm]; P = .002). The unadjusted
primary patency of BMSs at 12-, 24-, and 48-months following index stent placement was
57%, 47%, and 44%, respectively. This is compared to 62%, 49%, and 42% for CSs, and
81%, 66%, and 53% for DESs, respectively (log-rank P = .044). In adjusted models,
however, there were no significant differences in primary patency among the stent types.
Compared to CSs however, DESs were associated with improved primary-assisted patency
(hazard ratio [HR] for patency loss: 0.35, P = .008) and secondary patency (HR: 0.32, P =
.011). Across the entire follow-up period, stent occlusions occurred in 38 (40%) BMS cases,
42 (57%) CSs, and 11 (19%) DESs (P < .001). Of these, acute limb ischemia (ALI) occurred
in 2 (5%) BMS cases, 14 (33%) CSs, and 1 (9%) DES (P = .010). After adjustment, the
relative risk of presenting with ALI as opposed to claudication was 27 times greater among
occluded covered stents compared to bare metal stents (P = .020). There were no significant
differences in AFS or all-cause mortality across the three cohorts.

Conclusions: For long-segment SFA lesions, DESs are associated with improved primaryassisted and secondary patency over long-term follow-up. In the event of stent occlusion,
covered stents confer an increased risk of acute ischemia.
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BACKGROUND

Literature Review
Peripheral arterial disease
Peripheral arterial disease (PAD) is a chronic condition that significantly impedes
adequate circulation to the lower extremities. Caused by atherosclerosis, common PAD risk
factors include: age, race, smoking, diabetes, hyperlipidemia, hypertension, chronic renal
insufficiency, and genetic factors.1, 2 More recent literature has also implicated dietary
composition, inflammatory states, infection, and environmental toxins in the pathogenesis of
PAD.3 This becomes increasingly important as PAD is recognized as a marker for systemic
atherosclerosis and is a coronary artery disease risk equivalent among both men and women.4
Though the majority of lower extremity atherosclerotic disease is asymptomatic,
clinical manifestations of PAD range from intermittent claudication, defined as reproducible
lower extremity muscle discomfort on exertion that is relieved by rest5, to chronic limbthreatening ischemia (CLTI), largely identified by the presence of ischemic rest pain and/or
tissue loss (in the form of either ulceration or gangrene). The Society for Vascular Surgery
has developed the Lower Extremity Threatened Limb Classification System in order to
objectively stratify a given individual’s risk of lower extremity amputation based on the
presence of wounds, ischemia, and foot infection (WIfI).6 The WIfI classification system has
four clinical stages (stages 1-4), each associated with an increasing risk of limb loss.
Considering that WIfI stage 4 is associated with a 23% one-year amputation rate7, it is
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imperative to accurately identify and characterize the severity of PAD in order provide
therapy that maximizes an individual’s functional outcome.
Treatment for PAD relies on both lifestyle modification (smoking cessation and a
structured exercise regimen) as well as medical management of concomitant hypertension,
hyperlipidemia, and hyperglycemia.8 However, when a patient’s symptoms significantly limit
their daily activities or persist despite medical management, revascularization is often
recommended.1 This type of intervention, in turn, often requires treatment of the superficial
femoral artery (SFA), the most commonly diseased artery in lower extremity PAD.9, 10

Review of relevant anatomy
The SFA is the primary artery supplying the lower extremity. It originates from the
common femoral artery near the groin, traverses the length of the thigh, and crosses the
adductor canal in the distal thigh before diving posteriorly and turning into the popliteal
artery near the level of the knee (Figure 1). Since the popliteal artery subsequently goes on
to supply the distal lower extremity by way of three runoff vessels, arterial flow through the
SFA is critically important in the treatment of PAD.
The SFA’s anatomic location predisposes it to unique physical forces that have direct
implications on the durability of any operative intervention performed in the area. It is a long
artery, measuring as long as 35-40cm in some individuals. This considerable length, coupled
with a relatively high atherosclerotic disease burden undoubtedly poses unique challenges
and complexities to potential PAD-related treatments.10 Further, by traversing the thigh, the
SFA is subject to external biomechanical forces (torsion, contraction/elongation,
2
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Traditional therapeutic approaches
Management of long-segment SFA lesions greater than 15cm in length has
traditionally involved an open arterial bypass operation as indicated by consensus
recommendations.1 In such a procedure, a vein or prosthetic conduit is used to connect patent
arterial segments above and below the SFA occlusion, thereby reestablishing in-line blood
flow to the distal lower extremity. Though this continues to represent the current gold
standard10, the dramatic evolution of intraoperative imaging modalities and endovascular
therapy over the last two decades has shifted practice to a minimally invasive, endovascular
approach that confers less morbidity and faster recovery than open operations.13, 14

Endovascular stents and reported outcomes
Endovascular treatment modalities are vast and include numerous tools to treat
atherosclerotic SFA lesions. These therapeutic options can largely be classified as: 1)
percutaneous plain balloon angioplasty, or 2) angioplasty with additional scaffolding in the
form of intraarterial endoprostheses (i.e., endovascular stents; Figure 2). Though effective
for short, simple lesions, angioplasty has inferior patency rates when compared to stents for
more complex disease patterns.15 Therefore, primary endovascular stenting has become a
preferred treatment for long SFA lesions.

4

A.

B.

Figure 2. Endovascullar treatmentt modalities for lower exxtremity periipheral arterrial
ncludes: (A) plain balloo
on angioplastty in which aan endovasccular balloonn is
disease in
used to op
pen an athero
osclerotic lesion, and (B
B) angioplastty accompannied by stent
deploymeent in order to
t augment vessel
v
patenccy16.

nt types are currently used: 1) bare m
metal stents, 2) covered stents, and 33)
Three sten
bare metal
m
drug-eeluting stents (Figure 3)). Bare metall stents first revolutionizzed the field of
endov
vascular therrapy by prov
viding a morre durable opption than anngioplasty allone for posttangio
oplasty resid
dual stenosis greater than
n 50% of the vessel’s diaameter.15 In ccurrent form
m,
these devices are self-expand
ding nitinol stents
s
that arre flexible annd attempt too provide
sufficcient radial strength
s
to co
ombat the dy
ynamic biom
mechanical fforces actingg on the SFA
A.
Even
n with these characteristic
c
cs, however, reported 122-month prim
mary patencyy rates vary
greatly from 46%
% to 92% bassed on lesion
n length.10, 177 From a path
thophysiologgic perspective,
occlu
usion and failure of a barre metal sten
nt is largely ddriven by inttimal hyperpplasia, an
endotthelial prolifferative reacttion that occcurs throughoout the stentt’s length.

5

A.

B.

Figure 3. Among the different typ
pes of endovvascular stennts used in thhe treatmentt of
peripheral arterial disease, (A) sellf-expandingg nitinol baree metal stentts were
introduced first.18 (B)) Heparin-bo
onded covereed stents usee a prostheticc ePTFE liniing
along the luminal surfface of the nitinol
n
scaffoolding aimedd at preventinng in-stent
19
occlusion
n. Drug-elu
uting stents closely
c
resem
mble the baree metal stentt pictured in (A)
and are co
oated by an antiprolifera
a
ative agent inn further atteempts to impprove patenccy.

mpt to impro
ove patency rates, coverred stents weere introduceed. These deevices
In an attem
are esssentially thee same self-eexpanding nitinol
n
stents as describedd previouslyy, but are covvered
on their luminal surface
s
with heparin-bon
nded, expandded polytetraafluoroethyllene (ePTFE
E), a
prosth
hetic materiaal that preveents hyperplaasia-related iin-stent occllusion. Severral landmarkk
trials have studied patency raates of covered stents witth mixed ressults. To illuustrate,
6

VIASTAR20 reported a 12-month primary patency rate of 71% for covered stents used in
long-segment SFA lesions, as compared to 37% for bare metal stents. Similarly, the multicenter, single-arm VIPER trial21 reported primary patency rates as high as 88% when the
covered stent was optimally sized. At 36-months post-intervention, however, VIBRANT22
reported similar patency rates between covered and bare metal stents: 24% vs. 26%,
respectively. As with bare metal stents, the mechanism of failure of covered stents remains
intimal hyperplasia, but localized to the stent’s edges. Therefore, even if covered stents do
have improved short-term patency rates, any advantage seems to be extinguished within three
years of stent placement.
With continued advancement of endovascular technology, yet another type of stent
emerged in order to combat the risk of intimal hyperplasia-related in-stent occlusion. Drugeluting stents attempt to use local concentrations of antiproliferative agents to maintain stent
patency.15 Until September 2018 there was only one FDA-approved drug-eluting stent
available for use in the United States: the Zilver PTX stent (Cook Medical; Bloomington,
IN), a self-expanding nitinol stent with a polymer-free paclitaxel coating.23 Prospective
comparisons of drug-eluting stents to plain balloon angioplasty revealed an improvement in
five-year primary patency rates: 66% versus 43%, respectively.24

Reporting standards for stent patency
With the increase in the number of studies investigating stent patency, updated
reporting standards for the endovascular treatment of PAD were published in 2016 by the
Society for Vascular Surgery.25 These standards used two factors in defining patency: 1) the
7

timing of re-intervention, and 2) whether the intervention was performed for in-stent
occlusion (as opposed to stenosis). With these, three different types of patency were
described:
•

Primary patency – “the interval from the time of the original intervention until any
intervention designed to maintain or re-establish patency is performed”

•

Primary-assisted patency – “patency of the endovascular intervention achieved with
the use of additional or secondary surgical or endovascular procedures, as long as
occlusion of the primary treated site has not occurred”

•

Secondary patency – “patency obtained with the use of an additional or secondary
surgical or endovascular procedure after occlusion occurs.”

Current limitations of the literature
Though there have been several prospective studies attempting to elucidate outcomes
among these three stent types, significant gaps in the literature prevent direct comparability
and broad generalization of the results. A significant limitation is the wide range of lesion
lengths reported in these studies, with mean lesions measuring anywhere from 6.5cm among
drug-eluting stents26 to 19cm among covered stents.20-22 As lesion length can confound the
relationship between the type of stent used and its subsequent patency rate13, this difference
undoubtedly influences the interpretation of these results. Additionally, the variation in
follow-up time raging anywhere from 12 months to 5 years serves as yet another barrier to
the direct comparison of these stents. Taken together, though these stents are superior to
8

balloon angioplasty alone, the relative effectiveness and comparative outcomes among bare
metal, covered, and drug-eluting stents, particularly in long-segment SFA lesions, continue to
remain uncertain.

Public Health Significance
PAD is associated with significant morbidity and mortality burdens worldwide.10
Nationally, more than 15 million people over the age of 40 are estimated to have PAD. With
insurance claims data indicating an annual prevalence of 12% and an incidence of 3% 27, the
management of PAD is estimated to cost between $200-400 billion per year.14 Importantly,
the prevalence of PAD increases with age, reaching nearly 23% among Americans greater
than 80 years of age.27 Considering that PAD is a coronary artery disease risk equivalent, it is
not surprising that individuals with PAD also have a 2-3 times increased risk of all-cause
mortality within three years of diagnosis.28
In addition to a significant risk of mortality, PAD similarly negatively impacts quality
of life.29 Surgical intervention is performed at an estimated rate of approximately 600 per
100,000 people30, with intermittent claudication associated with a 1% per year risk of limb
loss1, 31 as compared to a substantially higher one-year amputation risk of 25% among CLTI
patients.1, 32 Most striking, however, is the nearly 50% one-year mortality rate among
Medicaid PAD patients who undergo a major lower extremity amputation.27 With such
profoundly negative impacts on a substantial proportion of the population, identifying
effective and durable treatment options for PAD is crucial for avoiding amputation,
maintaining quality of life, and decreasing premature PAD-related deaths.
9

Specific Aims
The objective of this study was to identify pragmatic differences in clinically-relevant
outcomes associated with the three primary stents types used in the treatment of longsegment, atherosclerotic, superficial femoral artery (SFA) disease. The central hypothesis
was that drug-eluting stents will have superior patency and limb preservation rates when
compared to bare metal and covered stents. The enduring goal of this study was to identify
the optimal endovascular treatment modality for these complex SFA lesions in an attempt to
minimize PAD-associated morbidity. To accomplish these goals and objectives, three
specific aims were addressed:
Aim 1: To assess long-term primary patency rates among bare metal, covered, and
drug-eluting stents used for SFA lesions measuring at least 15cm in length. We hypothesized
that drug-eluting stents will have superior primary patency rates across long-term follow-up
of at least 12 months in duration.
Aim 2: To assess long-term primary-assisted patency, secondary patency,
amputation-free survival, and all-cause mortality rates among the three stent types. We
hypothesized that drug-eluting stents will have greater primary-assisted and secondary
patency when compared to bare metal and covered stents. We also hypothesized that there
will be no significant difference in either amputation-free survival or all-cause mortality.
Aim 3: To assess differences in patient symptomatology in the event of stent
occlusion. We hypothesized that covered stents are associated with a greater incidence of
acute limb ischemia at the time of stent occlusion when compared to bare metal and drugeluting stents.
10

METHODS
Study Design
A single-center, retrospective cohort study was conducted.

Study Setting
The setting for this study was the Michael E. DeBakey Veterans Affairs (VA)
Medical Center in Houston, TX.

Study Subjects
Subjects were included in the study if they: 1) were an adult (at least 18 years of age);
2) had an endovascular stent successfully placed for a symptomatic, long-segment,
atherosclerotic SFA lesion measuring at least 15cm in length, with technical success defined
as residual stenosis of less than 30% on completion angiography; and 3) had the index stent
placed between May 2008 and December 2017. Of note, “symptomatic” was defined as a
preoperative indication of intermittent claudication, ischemic rest pain, and/or tissue loss,
with or without concomitant infection.
Patients were excluded from the study if they: 1) underwent an index operation for a
target lesion in a vessel other than the SFA; 2) required a concomitant open arterial bypass to
address the index SFA lesion; 3) did not attain intraoperative restoration of arterial flow
across the target lesion as evident on completion angiogram; or 4) were pregnant at the time
of operative intervention. Patients were also excluded if the stented arterial segment crossed
the patella and terminated in the below-knee popliteal artery.
11

Data Collection
Data was collected exclusively through electronic medical review and data
abstraction. Prospective data was not collected, no biological specimens were obtained, and
no patients were contacted for this retrospective cohort study.
The exposure of interest was the type of stent used to treat the long-segment SFA
lesion: bare metal, covered, or drug-eluting. The primary outcome of interest was primary
patency. Secondary outcomes of interest included: primary-assisted patency, secondary
patency, interventions required to maintain patency, patient symptomatology in the event of
stent occlusion, amputation-free survival (defined as survival without a major lower
extremity amputation proximal to the ankle), and all-cause mortality. Stent occlusion was
primarily determined by duplex ultrasonography, computed tomography scan, or
angiography showing no flow through the stent. Patency was determined based on definitions
provided by the Society for Vascular Surgery reporting standards.25 Additionally, baseline
data on the following pre-operative confounders was collected within six months of stent
placement: demographics, comorbidities, medication use, and smoking history (specific
variables are included in Table I and Table II).

Data Handling
All data collected through electronic medical review and data abstraction were
protected by robust firewalls and institutional computers. Additionally, the data folders
further restricted access to those that were cleared to view the data (i.e., the principal
investigator and research staff).
12

Data Analysis
Continuous variable distributions were visualized and assessed for normality.
Descriptive statistics among the three cohorts (bare metal, covered, and drug-eluting stents)
were presented and compared using either analysis of variance (ANOVA) or the nonparametric Kruskal-Wallis test. A Bonferroni correction was applied when assessing pairwise
comparisons among the three cohorts. Proportions for categorical variables were compared
using Pearson’s chi-square test or Fisher’s exact test. Kaplan-Meier survival estimates were
used to assess unadjusted patency rates (including primary, primary-assisted, and secondary
patency) and amputation-free survival. Cox proportional hazards regression models were
used to control for clinically and statistically significant confounders. An adjusted
multinomial logistic regression model was also used to assess patient symptomatology in the
event of stent occlusion. Statistical significance was set at a two-sided alpha of 0.05. All
statistical analyses were performed using Stata 14.0 (StataCorp; College Station, TX).

Human Subjects and Safety Considerations
This study was approved by the Baylor College of Medicine Institutional Review
Board as well as the VA Research and Development Committee. As requested by the
UTHealth Committee for Protection of Human Subjects, a SMART IRB reliance agreement
was also established between Baylor College of Medicine (the lead site) and UTHealth.

13

JOURNAL ARTICLE
Long-Term Outcomes after Endovascular Stent Placement for Long-Segment
Superficial Femoral Artery Lesions

Journal of Vascular Surgery

INTRODUCTION
Complex, long-segment atherosclerotic disease of the superficial femoral artery (SFA) is a
persistently challenging clinical dilemma.1 Based on consensus recommendations, this
pattern of disease has traditionally been managed by surgical revascularization.2 Currently,
however, with the continued evolution of therapeutic capabilities, an endovascular approach
is frequently pursued even for complex femoropopliteal disease.3

In the setting of this increased technical feasibility, there is relatively limited data on
outcomes following primary stent placement for long-segment SFA disease, and there is even
less data available that directly compares the different types of stents routinely used for this
indication.4, 5 Since the sustained durability of plain balloon angioplasty is limited in complex
lesions5, 6, addressing this gap in the literature will assist in defining the specific role
endovascular stents have in managing long-segment SFA disease.

The objective of this study was to assess the comparative effects of bare metal, covered, and
drug-eluting stents on clinical outcomes for the treatment of long-segment SFA disease.
14

METHODS
Patient population and eligibility. A single-center, retrospective cohort study was
performed. Adult patients at the Michael E. DeBakey VA Medical Center were included in
the study if they successfully received an endovascular SFA stent for an atherosclerotic
segment measuring at least 15cm in length between May 2008 and December 2017.
Technical success was defined as reestablishment of SFA patency with flow across the target
lesion with less than 30% residual stenosis on completion angiography.7 Cases were
excluded if the stented segment traversed the level of the patella and terminated in the belowknee popliteal artery. This study was approved by the Veterans Affairs Research and
Development Committee as well as the Baylor College of Medicine Institutional Review
Board.

Exposure of interest. The cases were categorized based on the type of index stent used to
treat the lesion: 1) self-expanding nitinol bare metal stents (BMSs), 2) covered stents (CSs),
or 3) drug-eluting stents (DESs). When deploying a CS across a lesion, care was taken to
preserve collateral vessels measuring more than 3mm in diameter8, and oversizing the stent
was avoided.9, 10 The CSs were self-expanding nitinol stents covered on their luminal surface
with heparin-bonded, expanded polytetrafluoroethylene (GORE VIABAHN Endoprosthesis;
W. L. Gore and Associates, Inc.; Flagstaff, AZ). The DESs were self-expanding nitinol stents
with a polymer-free paclitaxel coating (Zilver PTX; Cook Medical; Bloomington, IN).

15

Outcomes. The primary outcome was primary patency. Restenosis and occlusion were
largely documented by duplex ultrasonography, computed tomography scan, or digital
subtraction angiography. Secondary outcomes included: primary-assisted patency, secondary
patency, target lesion revascularization (TLR; defined by the first endovascular or open
reintervention on the target lesion), acuity of patient presentation in the event of stent
occlusion, amputation-free survival (AFS; defined as postoperative survival without a major
lower extremity amputation proximal to the ankle), and all-cause mortality. AFS was
restricted to patients who initially presented with chronic limb-threatening ischemia (CLTI,
defined as ischemic rest pain or tissue loss). Patency and TLR were defined in accordance
with the Society for Vascular Surgery reporting standards7, with estimates over time reported
among the entire cohort starting at the time of stent placement.9, 11

Confounding variables. Demographic data, preoperative comorbidities, and relevant
perioperative factors were collected. Specifically, models controlled for SFA lesion length,
runoff, CLTI on initial presentation, diabetes, end-stage renal disease, smoking history,
serum albumin, relevant medication use (aspirin, statin, clopidogrel), sex, and age8, 12-14.
Analyses of outcomes related to mortality were additionally adjusted for clinically relevant
comorbidities presented in Table 1.

Statistical analysis. Continuous variable distributions were visualized and assessed for
normality. Descriptive statistics among the three cohorts were compared using either analysis
of variance (ANOVA) or the non-parametric Kruskal-Wallis test for continuous variables. A
16

Bonferroni correction was applied when assessing pairwise comparisons among the three
cohorts. Proportions for categorical variables were compared using Pearson’s chi-squared
test or Fisher’s exact test. Kaplan-Meier survival estimates were used for time-to-event
analyses, and unadjusted differences between groups were tested using the log-rank test.
Multivariable Cox proportional hazards regressions were used to control for clinically and
statistically significant confounders. For outcomes related to patency, hazard ratios were
obtained that reflected the adjusted association between stent type and loss of patency. An
adjusted multinomial logistic regression model was used to assess patient presentation in the
event of stent occlusion. Statistical significance was set at a two-sided alpha of 0.05. All
statistical analyses were performed using Stata 14.0 (StataCorp; College Station, TX).
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RESULTS
Descriptive characteristics. A total of 205 patients accounted for 226 SFA lesions that were
included in the analysis. 95 (42%) lesions were treated with BMSs, 74 (33%) with CSs, and
57 (25%) with DESs. The cohort treated with DESs had a comparatively lower proportion of
men (P = .015), a greater prevalence of stroke (P = .007), and a lower serum albumin level (P
= .010). There were no significant differences across cohorts in mean age, prevalence of
either diabetes or end-stage renal disease, or smoking history. De novo atherosclerotic lesions
comprised the vast majority of the lesions treated across all cohorts (BMS: 93 [98%], CS: 66
[89%], DES: 51 [90%], P = .107). Descriptive characteristics of the three cohorts are
presented in Table I.

A greater proportion of DESs were placed for an indication of CLTI (BMS: 39%, CS: 31%,
DES: 67%, P < .001), and the three cohorts varied with respect to the distribution of runoff
vessels (P = .014). The median lesion length treated in this analysis was 25cm, but when
compared across cohorts, there were differences present in both lesion length (P = .002) and
follow-up times (P < .001). During index stent placement, coexisting iliac lesions were
treated endovascularly in 10 (11%) BMS cases, 10 CS cases (14%), and 9 (16%) DES cases
(P = .629). Common femoral artery endarterectomy was performed concomitantly in three
(4%) CS cases, and in three (5%) DES cases. Perioperative details are presented in Table II.

Patency. A total of 113 (50%) cases maintained primary patency over the course of the study
(BMS: 44 [46%], CS: 28 [38%], DES: 41 [72%], P < .001; Table III). The unadjusted
18

Kaplan-Meier estimates for primary patency at 12-, 24-, and 48-months were 57%, 47%, and
44% for the BMS cohort; 62%, 49%, 42% for CSs; and 81%, 66%, 53% for DESs,
respectively (P = .044; Figure 1). In the adjusted model, there was no statistical association
between stent type and primary patency (Table IV).

The unadjusted 12-, 24-, and 48-month Kaplan-Meier estimates for primary-assisted patency
were 68%, 63%, and 60% for BMSs; 67%, 51%, and 45% for CSs; and 89%, 79%, and 60%
for DESs, respectively (P = .004; Supplemental Figure 1). The corresponding estimates for
secondary patency were 74%, 69%, and 66% for BMSs; 75%, 59%, and 51% for CSs; and
89%, 81%, and 74% for DESs (P = .011; Supplemental Figure 2). After adjustment, DESs
had a significantly improved primary-assisted patency (HR for patency loss: 0.35, P = .008)
and secondary patency (HR for patency loss: 0.32, P=.011; Table IV) compared to CSs.

Target lesion revascularization. Across the study’s follow-up, a total of 83 (Table III)
stented lesions collectively required 84 endovascular (BMS: 31/84 [37%], CS: 42/84 [50%],
DES: 11/84 [13%]) and 39 open (BMS: 14/39 [36%], CS: 23/39 [59%], DES: 2/39 [5%])
revascularization attempts. The vast majority of both endovascular (76/84 [90%]) and open
(32/39 [82%]) reinterventions occurred within 18 months of initial stent placement.

The unadjusted Kaplan-Meier estimates for freedom from TLR at 12-, 24-, and 48-months
were 72%, 64%, and 61% for BMSs; 71%, 59%, and 54% for CSs; 87%, 77%, and 64% for
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DESs, respectively (P = .042; Supplemental Figure 3). After adjustment, however, there
was no significant association between stent type and TLR (Table IV).

Presentation upon stent occlusion. Stent occlusions occurred in 38 (40%) lesions treated
with BMSs, 42 (57%) CSs, and 11 (19%) DESs (P < .001). Details of patient presentation at
the time of stent occlusion are presented in Table III. In particular, the unadjusted rate of
ALI was significantly different among the stent types (BMS: 5%, CS: 33%, DES: 9%; P =
.010). Among the cases with ALI, eight (47%) required an open arterial bypass of the target
lestion, all of whom were in patients initially treated with CSs. Additionally, eight (47%)
individuals who developed ALI subsequently required a major lower extremity amputation,
with six (75%) of these amputations in patients with CSs. After adjustment, the relative risk
(RR) of presenting with ALI as opposed to claudication was 27 times greater among
occluded covered stents compared to bare metal stents (P = .020; Table V). Compared to
other stents, DESs were not associated with a significantly increased risk of either ALI or
ischemic rest pain/tissue loss in the event of stent occlusion.

Amputation-free survival. Among patients with an operative indication of CLTI, there was
a total of 18 (18%) major lower extremity amputations (Table III). The unadjusted 12-, 24-,
and 48-month Kaplan-Meier estimates for AFS were 58%, 47%, and 44% for BMSs; 83%,
69%, and 34% for CSs; and 70%, 70%, and 59% for DESs, respectively (P = .528; Figure 2).

20

In the adjusted model, there were no associations between stent type and AFS in patients
with CLTI (Table IV).

Of the 128 SFA lesions treated in patients with claudication, there were a total of seven
(5.5%) major lower extremity amputations, all of which occurred in the CS cohort. Further,
with respect to the timing of limb loss, four of these seven (57%) amputations occurred more
than 12 months after the SFA was initially stented.

All-cause mortality. Among all patients, 42 (46%) individuals with BMSs, 30 (43%) with
CSs, and 10 (19%) with DESs (P = .003; Table III) died during the follow-up period. The
unadjusted Kaplan-Meier survival estimates at 12-, 24-, and 48-months were 90%, 80%, and
77% for BMSs; 94%, 87%, and 72% for CSs; and 85%, 85%, and 77% for DESs,
respectively (P = .999; Figure 3). After adjustment, there was no significant association
between the stent type and all-cause mortality (Table IV). This association was further
maintained when DESs were compared to all other stents collectively (HR 0.57, 95% CI
0.25-1.34, P = .199).
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DISCUSSION
In this study, we directly compared the long-term outcomes of bare metal, covered, and drugeluting stents in the treatment of symptomatic, long-segment SFA lesions measuring at least
15cm in length. After robust adjustment for clinically and statistically significant
confounders, our results did not identify a significant difference among these stent types with
respect to long-term primary patency, TLR, or all-cause mortality when used to treat
complex SFA disease. DESs appear to have improved primary-assisted and secondary
patency across long-term follow-up, and though there is not a difference among the stents
with respect to amputation-free survival, occlusion of covered stents is associated with a
significantly increased risk of acute ischemia relative to bare metal stents.

Despite landmark trials studying these outcomes, considerable gaps in the literature prevent
direct comparison and generalization of the results to long SFA lesions. A significant
limitation is the wide range of lesion lengths reported in these studies, with mean lesions
measuring anywhere from 6.5cm among drug-eluting stents13 to 19cm among covered
stents.4, 5, 9 Since the cumulative length of the index lesion can influence relevant outcomes14,
this difference undoubtedly impacts the interpretation of these studies relative to one another.
Additionally, the variation in preoperative symptoms, study design, eligibility criteria,
outcome definitions, and reported follow-up all serve as additional barriers to the direct
comparison of these results.6, 15 Our analysis attempts to provide a head-to-head assessment
among these widely used endovascular prostheses, thereby helping to define the pragmatic
role of these stents when specifically used in long-segment SFA lesions.
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The unadjusted 12-month primary patency estimates for BMSs, CSs, and DESs in this
analysis were 57%, 62%, and 81%, respectively. When compared to the available literature
that either exclusively investigates long-segment SFA disease or provides sub-group analysis
of complex lesions, 12-month primary patency for these stents ranges from 37-83% for
BMSs5, 16, is reported to be 71% for CSs5, and ranges from 53-78% for DESs.17, 18 Though
our observed primary patency for CSs appears to be lower than that in the literature (62% vs.
71%)5, it actually compares favorably to a 12-month primary patency of 53% reported in the
VIBRANT trial which included lesions with a mean length of 18cm.

After adjustment for relevant confounders, there was no statistically significant difference in
primary patency rates among the three stent types included in this analysis. In contrast, DESs
appear to provide an improvement in primary-assisted and secondary patency when
compared to CSs in our study. Interestingly, this association with secondary patency is not
readily evident from the literature if only assessing 12-month Kaplan-Meier estimates which
actually suggest the opposite: higher patency rates in CSs (90-92%5, 9) compared to DESs
(80-88%17, 19). Not only does this underscore the advantage of direct comparison for these
stents, but it also highlights the role of appropriate risk adjustment when interpreting patency
rates over time.

In this study, we present Kaplan-Meier estimates through four years of follow-up for DESs
and five years for BMSs and CSs. Based on these rates and corresponding confidence
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intervals, patency generally appears relatively stable beyond 18 months after SFA stenting.
Among DESs used to treat shorter lesions, similar trends are reported in the literature for
primary patency over a five-year follow-up period.20 Though this has also been implied for
long-segment lesions, patency for complex disease patterns beyond 24 months is infrequently
reported.4, 16 Considering that the vast majority of the reinterventions in this study
correspondingly occurred within the first 1-2 years, these findings underscore the importance
of routine follow-up during the first 18 months after a complex SFA lesion is treated.2

In the event of stent occlusion, those treated with covered stents were significantly more
likely to present with ALI as opposed to claudication when compared to bare metal stents.
This was true even after adjustment for baseline comorbidities, medications, lesion length,
runoff, and preoperative CLTI. These findings support similar observations reported by
others, 12, 21, 22 and may be due to the mechanism by which stents fail. In the case of BMSs,
for example, in-stent restenosis occurs gradually as a result of neointimal hyperplasia
throughout the length of the stent.4, 5, 23 In CSs, however, this proliferative reaction is located
at the stent’s edges, a physiological consideration that can cause thrombosis of the stent graft
over a relatively short period of time, resulting in an acute presentation.24, 25

In randomized controlled trials, no differences were noted in amputation rates between BMSs
and either CSs or DESs.4, 5, 13 Similarly, we did not observe a difference in either unadjusted
or adjusted amputation-free survival estimates among patients with CLTI. With respect to
mortality, however, meta-analytic pooled data (n = 4432 cases; 11% with CLTI) indicates
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that five-year all-cause death is significantly increased in patients treated with paclitaxelcoated devices (including both balloons and stents).26 Another nationwide analysis of claims
data (n = 16,560; 51% CLTI), however, shows no association between paclitaxel-coated
devices and all-cause mortality.27 Though our multivariable analysis (which controlled for
comorbidities, medications, and initial presentation) did not reveal a difference in all-cause
mortality in this particular patient population with long SFA lesions, dedicated investigation
is necessary in order to accurately assess long-term survival.

The limitations of this study must also be considered. Compared to the other stent types, the
DES cohort had a smaller sample size with shorter follow-up. Though this is expected given
that DESs are a relatively newer technology, this inherently decreases the relative accuracy
of the cohort’s long-term outcome estimates. This is most evident in our analyses of AFS as
restricted to patients with CLTI, and clinical presentation in the event of stent occlusion. This
may have additionally prevented us from identifying a significant difference in primary
patency across the cohorts. Additionally, with three exposure groups and the absence of
prospective randomization, there were statistically significant baseline and perioperative
differences among the cohorts. Even with robust risk adjustment that accounted for not only
these differences, but other clinically relevant confounders as well, the retrospective nature of
the study still imparts the possibility of residual confounding. Further, given our patient
population, these results are not directly generalizable to women.
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CONCLUSION
For long-segment SFA lesions treated with endovascular stents, drug-eluting stents appear to
have improved primary-assisted and secondary patency rates as compared to covered stents.
The majority of open and endovascular reinterventions occur within 18 months after stent
placement, which warrants routine follow-up during this time period. Though there is no
difference in amputation-free survival among patients with preoperative CLTI, covered stents
have an increased risk of presenting with acute limb ischemia in the event of stent occlusion,
an association that can influence decision-making algorithms and patient counseling.

26

Tables
Table I. Descriptive characteristics and comorbidities of cases included in the study
Variable
Age, years (mean, SD)
Male
Race/ethnicity
Caucasian
African
American
Other*
BMI, kg/m2
(mean, SD)
Hypertension
Hyperlipidemia
CAD
CHF
Myocardial infarction
CVA
Diabetes
Current smoking
Past smoking
COPD
ESRD
Albumin, g/dL
(median, IQR)
Preoperative
medications
Statin
Aspirin
Clopidogrel
Warfarin

Overall
(N=226)
65.0 (7.1)
221 (97.8)

Bare Metal Covered
(n=95)
(n=74)
65.4 (7.7) 64.0 (6.2)
94 (99.0)
74 (100)

Drug-Eluting
(n=57)
65.8 (6.9)
53 (93.0)

P-value
.277
.015

143 (63.3)
59 (26.1)

56 (59.0)
31 (32.6)

54 (73.0)
13 (17.6)

33 (57.9)
15 (26.3)

24 (10.6)
28.2 (5.1)

8 (8.4)
27.7 (4.7)

7 (9.5)
29.0 (5.4)

9 (15.8)
28.1 (5.2)

207 (91.6)
175 (77.4)
109 (48.2)
36 (15.9)
37 (16.4)
23 (10.2)
123 (54.4)
112 (49.6)
83 (36.7)
33 (14.6)
3 (1.3)
3.7
(3.3-3.9)

84 (88.4)
72 (75.8)
40 (42.1)
17 (17.9)
19 (20.0)
7 (7.4)
56 (59.0)
45 (47.4)
42 (44.2)
15 (15.8)
2 (2.1)
3.7
(3.3-3.9)

70 (94.6)
59 (79.7)
38 (51.4)
10 (13.5)
13 (17.6)
4 (5.4)
33 (44.6)
42 (56.8)
25 (33.8)
10 (13.5)
0
3.7
(3.5-4.0)

53 (93.0)
44 (77.2)
31 (54.4)
9 (15.8)
5 (8.8)
12 (21.1)
34 (59.7)
25 (43.9)
16 (28.1)
8 (14.0)
1 (1.8)
3.5
(2.9-3.8)

.325
.830
.275
.742
.183
.007
.117
.293
.111
.908
.480

168 (74.3)
149 (65.9)
70 (31.0)
9 (4.0)

79 (83.2)
69 (72.6)
22 (23.2)
5 (5.3)

47 (63.5)
44 (59.5)
25 (33.8)
3 (4.1)

42 (73.7)
36 (63.2)
23 (40.4)
1 (1.8)

.015
.176
.070
.626

.125
.279

.010

Abbreviations: BMI, body mass index; CAD, coronary artery disease; CHF, congestive heart
failure; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident;
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ESRD, end-stage renal disease; IQR, interquartile range; SD, standard deviation
Note: Unless otherwise specified, variables are presented as n (%)
*Includes those categorized as Hispanic or Native American
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Table II. Perioperative characteristics of cases included in the study

Variables
Indication
Claudication
Rest pain
Tissue loss
ABI (mean, SD)
Toe pressure, mmHg
(mean, SD)
WIfI Stage
Stage 1
Stage 2
Stage 3
Stage 4
Runoff vessels
1
2
3
Lesion length, cm
(Median, IQR)
Number of stents
(Mean, SD)
Stent diameter, mm
(Median, IQR)
Operative time, hr
(Median, IQR)
Operative EBL, mL
(Median, IQR)
LOS, days
(Median, IQR)
Follow-up time, mo
(Median, IQR)

Overall
(N=226)

Bare Metal
(n=95)

Covered
(n=74)

DrugEluting
(n=57)

128 (56.6)
24 (10.6)
74 (32.7)
0.64 (0.22)

58 (61.1)
3 (3.2)
34 (35.8)
0.66 (0.19)

51 (68.9)
9 (12.2)
14 (18.9)
0.65 (0.25)

19 (33.3)
12 (21.1)
26 (45.6)
0.58 (0.22)

45.6 (26.2)

47.3 (23.5)

50.5 (28.8)

36.1 (24.3)

.015

77 (37.8)
82 (40.2)
27 (13.2)
18 (8.8)

31 (36.5)
33 (38.8)
13 (15.3)
8 (9.4)

29 (43.3)
31 (46.3)
5 (7.5)
2 (3.0)

17 (32.7)
18 (34.6)
9 (17.3)
8 (15.4)

.135

82 (36.3)
83 (36.7)
59 (26.1)

40 (42.1)
31 (32.6)
23 (24.2)

16 (21.6)
37 (50.0)
20 (27.0)

26 (45.6)
15 (26.3)
16 (28.1)

.014

25 (20-30)

28 (20-30)

26 (20-30)

20 (16-25)

.002

3.2 (1.1)

3.0 (1.1)

3.1 (0.9)

3.4 (1.1)

.125

5.8 (5.66.0)
1.9 (1.42.4)

6.2 (6.06.5)
2.0 (1.72.4)

6.0 (6.06.6)
1.9 (1.42.3)

6.4 (6.0-6.8)
1.7 (1.3-2.2)

P-value

<.001
.146

<.001
.007

25 (20-30)

25 (20-30)

25 (20-50)

20 (20-35)

.099

1 (0-1)

0 (0-1)

1 (0-1)

1 (0-3)

.005

55 (20-88)

67 (43-88)

82 (37-107)

20 (13-32)

<.001

Abbreviations: ABI, ankle-brachial index; EBL, estimated blood loss; hr, hours;
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IQR, interquartile range; LOS, hospital length of stay; mo, months; SD, standard deviation;
WIfI, wound, ischemia, foot infection classification
Note: Unless otherwise specified, variables are presented as n (%)
Missing observations: 22 missing observations in the WIfI Stage variable
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Table III. Unadjusted event rates for postoperative outcomes across the entire follow-up period
Outcome
Patency
Primary
Primary-assisted
Secondary
Target lesion revascularization
Symptom at stent occlusion2
Claudication
Rest pain or Tissue loss
ALI
Major amputation3
All-cause mortality4

Overall
(N=226)

Bare Metal
(n=95)

Covered
(n=74)

Drug-Eluting
(n=57)

P-value

113 (50.0)
135 (59.7)
147 (65.0)
83 (36.7)

44 (46.3)
57 (60.0)
62 (65.3)
35 (36.8)

28 (37.8)
32 (43.2)
37 (50.0)
37 (50.0)

41 (71.9)
46 (80.7)
48 (84.2)
11(19.3)

<.001
<.001
<.001
.001

38/91 (41.8)
34/91 (37.4)
17/91 (18.7)
18/98 (18.4)
82/205 (40.0)

16/38 (42.1)
18/38 (47.4)
2/38 (5.3)
11/37 (29.7)
42/91 (46.2)

18/42 (42.9)
10/42 (23.8)
14/42 (33.3)
2/23 (8.7)
30/70 (42.9)

4/11 (36.4)
6/11 (54.5)
1/11 (9.1)
5/38 (13.2)
10/53 (18.9)

.010
.070
.003

Abbreviations: ALI, acute limb ischemia
1

Event rates related to patency reflect the number of cases that maintained patency throughout the entire follow-up period.

2

Describes acuity of patient presentation in the event of stent occlusion. The denominators represent the total number of stent

occlusions over the entire follow-up period. Two individuals with bare metal stents were asymptomatic at the time of stent
occlusion, identified during noninvasive ultrasound surveillance.
3

Major amputations restricted to patients with a preoperative indication of CLTI.

4

All-cause mortality reported with respect to the number of patients, as opposed to the number of cases.
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Table IV. Adjusted associations between stent type and postoperative long-term outcomes
Outcome
Loss of patency1
Primary patency
Primary-assisted patency
Secondary patency
Target lesion revascularization
Amputation-free survival2
All-cause mortality

CS compared to BMS*
HR 95% CI P-value

DES compared to BMS*
HR
95% CI P-value

DES compared to CS*
HR 95% CI P-value

1.04
1.53
1.53
1.41
0.64
1.11

0.57
0.54
0.49
0.89
0.49
0.60

0.54
0.35
0.32
0.63
0.76
0.54

0.66-1.64
0.92-2.53

.849
.100

0.88-2.65
0.84-2.35
0.24-1.73
0.53-2.33

.128
.195
.378
.782

0.29-1.12
0.24-1.21
0.20-1.21
0.40-1.96
0.19-1.27
0.24-1.50

.102
.133
.122
.772
.141
.274

0.28-1.05
0.16-0.76
0.13-0.77
0.30-1.34
0.23-2.52
0.21-1.39

.071
.008
.011
.233
.657
.201

*Denotes the reference stent type
1

Hazard ratios for patency reflect the associations between stent type and the loss of patency over time.

2

Amputation-free survival restricted to patients with a preoperative indication of CLTI. Hazard ratios reflect the association

between stent type and having a major amputation or dying over time.
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Table V. Adjusted association between stent type and patient presentation in the event of stent occlusion
Clinical Presentation
Claudication
Rest pain or tissue loss
ALI

CS compared to BMS*
RRR
95% CI P-value
Ref.
Ref.
Ref.
0.64
0.14-2.89
.558
26.6 1.67-423.0
.020

DES compared to BMS*
RRR 95% CI P-value
Ref.
Ref.
Ref.
0.56 0.07-4.42
.578
13.3 0.17-1020
.243

*Denotes the reference stent type
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DES compared to CS*
RRR 95% CI P-value
Ref.
Ref.
Ref.
0.87 0.09-8.33
.906
0.50 0.02-15.5
.692

Figures
Figure 1. Unadjusted Kaplan-Meier estimates for primary patency by stent type
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Figure 2. Unadjusted Kaplan-Meier estimates for amputation-free survival by stent type,
restricted to patients initially presenting with CLTI
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Figure 3. Unadjusted Kaplan-Meier survival estimates by stent type among the entire cohort
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Supplemental Figure 1. Unadjusted Kaplan-Meier estimates for primary-assisted patency by
stent type
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Supplemental Figure 2. Unadjusted Kaplan-Meier estimates for secondary patency by stent
type
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Supplemental Figure 3. Unadjusted Kaplan-Meier estimates for freedom from target lesion
revascularization (TLR) by stent type
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